Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Receives Average Recommendation of "Hold" from Brokerages

Key Points

• Five analysts give Pharming Group an average recommendation of Hold (1 sell, 1 hold, 3 buy), with an average 12‑month price target of $38.33, well above the current share price.
• The company recently missed quarterly estimates—EPS $0.07 vs $0.15 expected and revenue $106.5M vs $111.8M—and the stock traded at $17.39 (up 2.4%) with a market cap of $1.22B and a P/E of 1,738.6.
• Pharming is a clinical‑stage biopharma whose lead product RUCONEST is approved for hereditary angioedema and which uses a proprietary transgenic platform to produce recombinant human proteins.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) has been given an average recommendation of "Hold" by the five analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $38.3333.

PHAR has been the topic of several research analyst reports. Oppenheimer reissued an "outperform" rating and issued a $41.00 price objective (down from $42.00) on shares of Pharming Group in a research note on Friday, March 13th. Zacks Research cut Pharming Group from a "hold" rating to a "strong sell" rating in a research report on Thursday, March 12th. Wall Street Zen raised Pharming Group to a "strong-buy" rating in a research report on Saturday, December 27th. Canaccord Genuity Group started coverage on Pharming Group in a research report on Friday. They set a "buy" rating and a $37.00 target price on the stock. Finally, Weiss Ratings raised Pharming Group from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Monday, March 30th.

Pharming Group Trading Up 2.4%

Shares of NASDAQ PHAR traded up $0.41 during midday trading on Friday, hitting $17.39. The company's stock had a trading volume of 782 shares, compared to its average volume of 27,501. The company has a current ratio of 2.59, a quick ratio of 2.03 and a debt-to-equity ratio of 0.33. The business's 50 day moving average is $16.23 and its two-hundred day moving average is $16.29. Pharming Group has a 12-month low of $7.79 and a 12-month high of $21.34. The firm has a market cap of $1.22 billion, a P/E ratio of 1,738.60 and a beta of 0.05.

Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings data on Thursday, March 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.08). Pharming Group had a return on equity of 1.08% and a net margin of 0.71%.The firm had revenue of $106.50 million during the quarter, compared to the consensus estimate of $111.76 million. As a group, equities research analysts expect that Pharming Group will post -0.2 EPS for the current year.

Institutional Trading of Pharming Group

Several hedge funds and other institutional investors have recently bought and sold shares of PHAR. NewEdge Advisors LLC boosted its position in Pharming Group by 11,310.3% during the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company's stock valued at $510,000 after acquiring an additional 28,615 shares in the last quarter. Millennium Management LLC bought a new stake in Pharming Group during the 4th quarter valued at $360,000. SmartHarvest Portfolios LLC bought a new stake in Pharming Group during the 4th quarter valued at $224,000. Finally, EverSource Wealth Advisors LLC bought a new stake in Pharming Group during the 2nd quarter valued at $32,000. Institutional investors own 0.03% of the company's stock.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company's lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.